Global Trial in APG2575 for Patients With CLL/SLL
ConditionCLL/SLL
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-99
SponsorAscentage Pharma Group Inc.
About this trial
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Patients that have documented CLL/SLL who meet iwCLL 2018 criteria for CLL treatment guidelines are eligible for treatment and must be receiving BTKi monotherapy for at least 12 months
ECOG Performance Status grade 0-2
Absolute neutrophil count ≥ 1.0 × 109/L
Disqualifiers
None
Trial design
Treatments tested in this trial
- lisaftoclax +BTK inhibitor
- BTK inhibitor
Treatment groups
400 Participants
are divided into 2 treatment groupsLocations
135Australia
Ascentage Investigative Site2250, Gosford Australia
Ascentage Investigative Site6000, Perth Australia
Ascentage Investigative Site2145, Westmead Australia
Belgium
Ascentage Investigative Site9000, Ghent Belgium
Sponsors and collaborators
Ascentage Pharma Group Inc.
Lead sponsor
Source ClinicalTrials.gov